Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
HUMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.75 - $9.97
Previous CloseN/A
Volume1.64M
Average Volume (3M)2.07M
Market Cap
$427.18M
Enterprise Value$646.13M
Total Cash (Recent Filing)$39.93M
Total Debt (Recent Filing)$28.86M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 09, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding128,668,490
10 Day Avg. Volume1,976,942
30 Day Avg. Volume2,066,257
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.44
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$13.17Price Target Upside296.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySymvess demonstrated clear and significant reductions in rate of amputation and infection compared to synthetic grafts.
Market LaunchHumacyte has officially launched SYMVESS, its acellular tissue-engineered vessel (ATEV), in the vascular trauma indication, marking a significant milestone for the company's first FDA-approved commercial indication.
Regulatory ApprovalSymvess was granted full approval by the FDA for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss.
Bears Say
Competitive LandscapeThe study indicated that Symvess outcomes should be similar to autologous vein at 30 days, which suggests that with further data Symvess could eventually displace autologous vein graft.
Market Adoption ChallengesThe early launch activities continue apace, with 26 hospitals initiating the VAC process, up from 21.
Market PenetrationTo ensure strong market penetration and adoption, Humacyte has undertaken a data-driven approach to market analysis, commercial execution, and reimbursement strategy.
---
Ownership Overview
5.94% Insiders
6.16% Mutual Funds
5.90% Other Institutional Investors
71.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $2.75 and its highest was $9.97 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $427.18M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is May 09, 2025 which is in 44 days.
How were Humacyte’s earnings last quarter?
Currently, no data Available
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.25.
How many shares outstanding does Humacyte have?
Humacyte has 128,668,490 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
---
Humacyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.17 (296.69% Upside)
$13.17 (296.69% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.30%
12-Months-Change
Fundamentals
Return on Equity
239.90%
Trailing 12-Months
Asset Growth
-23.18%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
---
HUMA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and strategic progress, particularly in the areas of regulatory achievements and clinical trial results. However, the delay in FDA review and increased financial losses pose notable challenges.Read More>---
HUMA Stock 12 Month Forecast
Average Price Target
$13.17
▲(296.69% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
10/22 ratings generated profit
1 Year Average Return
-5.76%
reiterated a buy rating 3 months ago
Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -5.76% per trade.
---